Press Room

Press Release / Oct 23, 2010

Aseptic Spray-Drying - Hovione’s latest offering

Loures, Portugal, 23rd October, 2009 - Hovione announced today that it has acquired an aseptic spray-drying production line, vial filling and back up utilities from Acusphere, a company located in Boston.

The equipment includes sterile filtration, aseptic spray drying, secondary drying and vial filling, as well as terminal sterilization systems, lyophilisation, WFI and clean steam production utilities. This acquisition is a great business opportunity, as it now provides Hovione access to equipment and knowhow for the production of sterile drug substance and sterile drug product.

“This is a very exciting move for Hovione, we are adding aseptic production -a tough new area of pharmaceutical manufacturing- to our offering. We have been considering aseptic production for some time and today we took the first step.” said Dave Hoffman, Head of Hovione’s Exclusives and Particle Design Business Units.

This acquisition adds to Hovione’s already impressive cGMP spray-drying facilities, which includes lab, pilot and various commercial scale production installations in Portugal, US and in Ireland. The range and versatility of the production equipment means Hovione can spray dry milligrams as well as deliver 400 tons/year from its Irish facility, spray drying HPAI’s (Highly Potent Active Ingredients) and now sterile compounds. Hovione’s in-house mathematical models, in combination with PAT and a QbD mindset, Hovione can solve the most complex solubility challenges.

About Hovione. Hovione is an international company dedicated to the cGMP development and manufacture of APIs and Intermediate Drug Products via particle design, serving exclusively the pharmaceutical industry. With four FDA inspected sites in the US, China, Ireland and Portugal, the company focuses on the most demanding projects, in the most regulated markets. The company also offers integrated API, particle design and formulation development and manufacturing. In the inhalation area, Hovione is the only independent company offering such a broad range of services.

For further information about Hovione, please visit the Hovione site at www.hovione.com or contact Corporate Communications (Isabel Pina, + 351 21 982 9362, e-mail: hello@hovione.com)

 

 

Also in the Press Room

See All

The CDMO’s New Jersey manufacturing site expansion will eventually cover more than 200,000 square feet. Portugal-based contract development and manufacturing organisation (CDMO) Hovione has completed an initial $100 million investment round in its East Windsor, New Jersey site. Once completed it will increase the facility’s footprint to more than 200,000 square feet and more than double its capacity for spray drying. Hovione CEO Jean-Luc Herbeaux said: “Since launching our New Jersey operations in 2002, Hovione has been one of the longest established European CDMOs in the United States. “This investment reinforces Hovione’s leadership in spray drying – a core technology platform where we have built extensive know-how and capabilities. By continuing to advance our platforms and expand capacity in the US, we are strengthening the foundation that enables our partners to bring complex medicines to patients more efficiently.” Spray drying is an increasingly important particle engineering technology for improving drug bioavailability through the amorphous solid dispersion (ASD) that can address bioavailability or crystallisation challenges. The initial phase of Hovione’s expansion will include a 31,000-square-foot building to house two size-3 spray dryers (PSD-3) designed for ASD production. Construction at the New Jersey site is already underway and the company plans to start GMP operations in the second quarter of 2026. The initiative is part of Hovione’s long-term strategy to grow its US operations and enhance its integrated drug substance, drug product intermediate and drug product capabilities. Herbeaux said: “This investment addresses growing customer demand for US-based capacity and integrated solutions that shorten development timelines and reduce tech transfer complexity. By consolidating development, scale-up, and commercial manufacturing within a single quality and governance framework, we provide customers with seamless execution from drug substance to drug product.” The company’s New Jersey expansion fits into its wider international growth plan that also includes capacity investments in Ireland and Portugal as it seeks to create a network of autonomous sites spanning the development and commercialisation of APIs, drug product intermediates and drug products.   Read the full article at EuropeanPharmaceuticalReview.com  

Press Clipping
European Pharmaceutical Review, 4 November 2025

Hovione doubles spray drying capacity with $100m US investment round

Nov 04, 2025

US-base manufacturing and the continued rise of peptides were among the key themes for CDMOs at CPHI Frankfurt 2025. Andrew Warmington reports. Hovione announced during this show that it has completed an initial $100 million investment phase in the expansion of its manufacturing footprint in East Windsor, New Jersey. The company was one of the first European CDMOs to set up in the US back in 2002. CEO Jean-Luc Herbeaux said that when he took over the role four years ago, Hovione's footprint in the US was limited and the site was reaching capacity limitations. (...) Read the full article on SpecChemOnline.com  

Article
Speciality Chemicals, Nov./Dec. 2025

Coming to America - Drug Product Focus

Nov 01, 2025

The latest from CDMOs, CMOs, and suppliers featuring Thermo Fisher Scientific, Lonza, SK pharmteco/Lotte Biologics, Hovione, Sai Life Sciences, BioCina, Alcami, Piramal Pharma/IntoCell and Roquette. Formulation Development/Drug Product Manufacturing: Hovione Completes Initial $100-M Investment Cycle in US Operations Hovione, a CDMO of drug substances and drug products, has completed an initial $100-million investment cycle at its site in East Windsor, New Jersey, as part of a strategy to increase its US operations and enhance its integrated drug-substance, drug-product intermediate, and drug-product capabilities. Upon completion, the site will cover more than 200,000 square feet.   The initial expansion phase includes a 31,000-square-foot building that will house two size-3 spray dryers (PSD-3) designed for production of amorphous solid dispersions (ASDs). This investment more than doubles Hovione’s spray-drying capacity in the US by expanding capabilities for ASD development and commercial manufacturing. Construction is underway at the New Jersey site, with GMP operations planned to start in the second quarter of 2026.  As part of this expansion, Hovione has also acquired additional adjacent land to enable future growth at the East Windsor site. The 125,000-square-foot greenfield will support large-scale production, including continuous and batch tableting capacity, and introduce the latest pharmaceutical technologies and digital innovation with enhanced quality control and R&D capabilities.    Read the full article at DCATvci.org  

Press Clipping
DCAT Value Chain Insights, 30 October 2025

Supplier News: Thermo Fisher, Lonza, SK pharmteco, Hovione & More

Oct 30, 2025

Also in Events

See All